The Family Heart Foundation, a leading U.S.-based organization dedicated to research, education, and advocacy in genetic dyslipidemias, has launched the Lp(a) AW(a)RE™ initiative — a nationwide effort to increase awareness, screening, and diagnosis of high Lipoprotein(a) [Lp(a)], a key but under-recognized genetic risk factor for cardiovascular disease.
It is estimated that one in five Americans carries a genetic mutation associated with elevated Lp(a) levels. However, testing rates remain alarmingly low — only 1% of the general population and 2% of individuals with established atherosclerotic cardiovascular disease (ASCVD) have ever been screened for Lp(a).
Initiative Overview
The two-year Lp(a) AW(a)RE™ program, initially sponsored by Eli Lilly and Company, aims to engage primary care physicians, health insurers, and policy makers to drive systemic change in cardiovascular prevention. The initiative includes educational symposia at professional conferences across the U.S., many of which will offer free Lp(a) screenings and informational materials for clinicians and patients.
Cardiovascular disease causes one out of every three deaths in America. The Family Heart Foundation’s mission is to prevent premature heart disease by addressing genetic risk factors such as high Lp(a). Through Lp(a) AW(a)RE, the organization aims to empower healthcare professionals and the public with education, real-world stories, and access to testing—ultimately improving detection and management of this overlooked condition.
Understanding the Risk
High Lipoprotein(a) poses a triple threat for early cardiovascular disease — promoting clotting, arterial blockage, and inflammation in blood vessels supplying the heart, brain, and limbs. Individuals with elevated Lp(a) are prone to earlier and more aggressive ASCVD onset, often during their most productive years.
Despite this, Lp(a) is not yet included in standard lipid panels, and clinician awareness remains low. Research indicates that managing other cardiovascular risk factors aggressively can significantly reduce overall risk, yet many insurers still do not cover Lp(a) testing.
Next Phase: From Awareness to Action
As part of its ongoing efforts, the Family Heart Foundation plans to launch the Lp(a) Awareness to Action campaign in early 2026. This will include a dedicated consumer website, free at-home Lp(a) screening kits, and personalized support through the Foundation’s Care Navigation Center to guide individuals through testing and follow-up care.
Through the Lp(a) AW(a)RE™ initiative, the Family Heart Foundation aims to close critical gaps in education, testing, and early intervention—helping millions reduce their risk of premature cardiovascular disease.
